Crossbow Therapeutics, Inc. — Form D
Crossbow Therapeutics, Inc. of Cambridge, MA, a company, filed a Form D exempt-offering notice with the SEC on 2025-09-30. The offering totals $80.0M, of which $30.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-09-30
- Form: D
- Accession: 0000905148-25-003444
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $80.0M
- Amount sold: $30.3M
- Remaining: $49.8M
- Investors: 17
- Date of first sale: 2025-09-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-559257
Issuer
- Name: Crossbow Therapeutics, Inc.
- CIK: 0001972912
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 1030 Massachusetts Ave, Suite 210, Cambridge, MA, 02138
- Phone: 860-501-1600
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Sakae Asanuma | Director | Cambridge, MA |
| Charles Baum | Director | South San Francisco, CA |
| Alexandra Cantley | Director | Newton, MA |
| Todd Foley | Director | South San Francisco, CA |
| Alon Lazarus | Director | Cambridge, MA |
| Irena Melnikova | Director | Cambridge, MA |
| Briggs Morrison | Director | Cambridge, MA |
| Briggs Morrison | Executive Officer | Cambridge, MA |
| Alexander Nolte | Executive Officer | Cambridge, MA |
| Dmitri Wiederschain | Executive Officer | Cambridge, MA |
| Briggs Morrison | Promoter | Cambridge, MA |
| Geraldine Paulus | Executive Officer | Cambridge, MA |
Other filings by this issuer (1)
More